1
|
Broutin A, Delrieu J, Blanc C, Esclassan R, Nasr K, Marty M, Canceill T, Noirrit E. Description and Durability of the Various Indirect Restoration Techniques in Molar-Incisor Hypomineralisation: A Systematic Review. Eur J Prosthodont Restor Dent 2024; 32:91-101. [PMID: 37988613 DOI: 10.1922/ejprd_2557broutin11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 09/17/2023] [Indexed: 11/23/2023]
Abstract
Molar-incisor hypomineralisation (MIH) is a qualitative defect of the enamel structure. Indirect restorations may represent the most suitable therapeutic solutions for patients presenting MIH with tooth restorative procedures. This systematic review aims to determine the feasibility of indirect restorations. MATERIALS AND METHODS A systematic review has been performed and is reported following the PRISMA guidelines. It was performed on three databases (PubMed, Science Direct, and Google Scholar). Ten articles were included. RESULTS Only two articles reported the use of CAD/CAM technologies, whereas the other eight preferred conventional registration and handmade stratification for ceramics. All indirect bonded restorations made of composite resins or ceramics had significant success rates. A temporary material was placed in most of the articles. There was no clear consensus for tissue conditioning before bonding. Depending on the authors and the articles, the follow-up period extended from 2 months to 6 years. CONCLUSIONS The survival rate and the non-invasive procedures of indirect restorations are two main arguments that can help dental practitioners in daily practice. Development of CAD/ CAM technologies adds new perspectives in the registration, the design and production. However, more clinical trials are needed to confirm the conclusions.
Collapse
Affiliation(s)
- A Broutin
- CHU Toulouse, Odontology Unit, Toulouse, France
- Centre for Anthropobiology & Genomics of Toulouse (CAGT) CNRS UMR 5288, Université Paul Sabatier, Toulouse, France
| | - J Delrieu
- CHU Toulouse, Odontology Unit, Toulouse, France
| | - C Blanc
- CHU Toulouse, Odontology Unit, Toulouse, France
| | - R Esclassan
- CHU Toulouse, Odontology Unit, Toulouse, France
- Centre for Anthropobiology & Genomics of Toulouse (CAGT) CNRS UMR 5288, Université Paul Sabatier, Toulouse, France
| | - K Nasr
- CHU Toulouse, Odontology Unit, Toulouse, France
| | - M Marty
- CHU Toulouse, Odontology Unit, Toulouse, France
- LIRDEF (Laboratoire Interdisciplinaire de Recherche en Didactique Education et Formation, Université Paul Valery Montpellier 3, France
| | - T Canceill
- CHU Toulouse, Odontology Unit, Toulouse, France
- InCOMM (Intestine ClinicOmics Microbiota & Metabolism) UMR1297 Inserm/Université Toulouse III, French Institute of Metabolic and Cardiovascular Diseases (i2MC), Toulouse, France
| | - E Noirrit
- CHU Toulouse, Odontology Unit, Toulouse, France
- UMR n°7268 ADES EFS CNRS, Marseille, France
| |
Collapse
|
2
|
Jin J, Ran Z, Noseda E, Roubert B, Marty M, Mezzacasa A, Göring UM. A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China. Front Med 2024; 18:98-108. [PMID: 37897561 DOI: 10.1007/s11684-023-1001-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 04/01/2023] [Indexed: 10/30/2023]
Abstract
Iron deficiency (ID) and ID anemia (IDA) pose significant public health concerns in China. Although iron sucrose (IS) treatment is well-established in the country, ferric carboxymaltose (FCM) offers the advantage of higher doses and fewer infusions. This open label, randomized, controlled, non-inferiority trial was conducted at multiple sites in China to compare the outcomes of FCM (maximum of 2 doses, 500 or 1000 mg iron) and IS (up to 11 infusions, 200 mg iron) treatments in subjects with IDA. The primary endpoint was the achievement of hemoglobin (Hb) response (an increase of ⩾2 g/dL from baseline) within 8 weeks, whereas secondary endpoints included changes in Hb, transferrin saturation, and serum ferritin levels. Among the 371 randomized subjects, a similar percentage of subjects treated with FCM and IS achieved Hb-response (FCM 99.4%, IS 98.3%), thereby confirming the non-inferiority of FCM compared with IS (difference 1.12 (-2.15, 4.71; 95% confidence interval (CI))). Furthermore, a significantly higher proportion of FCM-treated subjects achieved early Hb-response at Week 2 (FCM 85.2%, IS 73.2%; difference 12.1 (3.31, 20.65; 95% CI)). Additionally, the increase in TSAT and serum ferritin levels from baseline was significantly greater at all time points for FCM-treated subjects. The safety profiles of FCM and IS were comparable, with the exception of transient hypophosphatemia and pyrexia, which are consistent with FCM's known safety profile. In conclusion, FCM proves to be an efficacious treatment for IDA, providing faster Hb-response and correction of ID with fewer administrations than IS.
Collapse
Affiliation(s)
- Jie Jin
- The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, 310058, China
| | - Zhihua Ran
- Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | | | | | | | | | | |
Collapse
|
3
|
Marty M, Chiaverini C, Milon C, Costa-Mendes L, Kémoun P, Mazereeuw-Hautier J, Joseph C. Perception of Oral Health-Related Quality of Life in Children with Epidermolysis Bullosa: A Quantitative and Qualitative Study. JDR Clin Trans Res 2023; 8:349-355. [PMID: 35993264 DOI: 10.1177/23800844221118362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
KNOWLEDGE TRANSFER STATEMENT The results of this study confirm the difficulties experienced by patients in the oral sphere. They also show that patients are able to adapt and that their demands go beyond functional rehabilitation. This work should encourage dental practitioners to be part of the overall management of the disease, involving regular checkups, preventive dental measures, and oral hygiene education. Therefore, more effective communication is required, not only between the dental and dermatological teams but also with the parents and caregivers.
Collapse
Affiliation(s)
- M Marty
- Universite Toulouse III Paul Sabatier, Toulouse, France
| | - C Chiaverini
- University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azu, France
| | - C Milon
- University Paul Sabatier Toulouse III Faculty of Dental Surgery, Toulouse, Midi-Pyrénées, France
| | - L Costa-Mendes
- University Paul Sabatier Toulouse III Faculty of Dental Surgery, Toulouse, Midi-Pyrénées, France
| | - P Kémoun
- University Paul Sabatier Toulouse III Faculty of Dental Surgery, Toulouse, Midi-Pyrénées, France
| | | | - C Joseph
- University of Cote d'Azur, Nice, France
| |
Collapse
|
4
|
Rivière P, Le Chevillier A, Rullier A, Marty M, Schurr E, Lapuyade B, Célerier B, Fernandez B, Bessissow T, Treton X, Uzzan M, Poullenot F, Berger A, Zerbib F, Laharie D. Deep ulcers are associated with increased C-reactive protein in active ulcerative colitis. Dig Liver Dis 2023; 55:1194-1200. [PMID: 37244790 DOI: 10.1016/j.dld.2023.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 05/01/2023] [Accepted: 05/01/2023] [Indexed: 05/29/2023]
Abstract
BACKGROUND Increased C-reactive protein (CRP) is used to diagnose and predict response to treatment in acute severe ulcerative colitis (UC). AIMS To investigate the connection between CRP elevation and deep ulcers in UC. METHODS Patients with active UC were enrolled in a multicenter prospective cohort and a retrospective cohort of consecutive patients undergoing colectomy from 2012 to 2019. RESULTS Forty-one (9 (22%) with deep ulcers) patients were included in the prospective cohort: 4/5 (80%) patients with CRP > 100 mg/L, 2/10 (20%) patients with CRP between 30 and 100 mg/L and 3/26 (12%) patients with CRP < 30 mg/L had deep ulcers (p = 0.006). In the retrospective cohort [46 patients (31 (67%) with deep ulcers)], 14/14 (100%) patients with CRP > 100 mg/L, 11/17 (65%) patients with CRP between 30 and 100 mg/l and 6/15 (40%) patients with CRP < 30 mg/L had deep ulcers (p = 0.001). Positive predictive value of CRP > 100 mg/l for presence of deep ulcers was 80% and 100% in both cohorts, respectively. CONCLUSIONS CRP elevation is a robust surrogate marker for presence of deep ulcers in UC. Elevated CRP or presence of deep ulcers could influence the choice of medical therapy in acute severe UC.
Collapse
Affiliation(s)
- P Rivière
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France; Program in Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, Québec, Canada
| | - A Le Chevillier
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France
| | - A Rullier
- CHU de Bordeaux, Hôpital Pellegrin, Pathology department - Université de Bordeaux, Bordeaux F-33000, France
| | - M Marty
- CHU de Bordeaux, Hôpital Haut-Lévêque, Pathology department - Université de Bordeaux, Bordeaux F-33000, France
| | - E Schurr
- Program in Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, Québec, Canada
| | - B Lapuyade
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Radiology department - Université de Bordeaux, Bordeaux F-33000, France
| | - B Célerier
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Abdominal surgery department - Université de Bordeaux, Bordeaux F-33000, France
| | - B Fernandez
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Abdominal surgery department - Université de Bordeaux, Bordeaux F-33000, France
| | - T Bessissow
- Division of Gastroenterology and hepatology, McGill University Health Centre, Montreal, Canada
| | - X Treton
- Paris IBD Center, Groupe Hospitalier Privé Ambroise Paré-Hartmann, 25 bd Victor Hugo, Neuilly/Seine 92200, France
| | - M Uzzan
- Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Gastroenterology department, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Créteil F-94010, France
| | - F Poullenot
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France
| | - A Berger
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France
| | - F Zerbib
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France
| | - D Laharie
- CHU de Bordeaux, Centre Medico-chirurgical Magellan, Hôpital Haut-Lévêque, Gastroenterology department, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France.
| |
Collapse
|
5
|
Liu J, Zuo L, Walpen S, Bernard L, Marty M, Enoiu M. Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study. Nephron Clin Pract 2023; 148:22-33. [PMID: 37473746 PMCID: PMC10794965 DOI: 10.1159/000531869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 06/20/2023] [Indexed: 07/22/2023] Open
Abstract
INTRODUCTION This study aimed to investigate the efficacy and safety of sucroferric oxyhydroxide (SFOH) versus sevelamer carbonate in controlling serum phosphorus (sP) in adult Chinese dialysis patients with hyperphosphataemia (sP >1.78 mmol/L). METHODS Open-label, randomised (1:1), active-controlled, parallel group, multicentre, phase III study of SFOH and sevelamer at starting doses corresponding to 1,500 mg iron/day and 2.4 g/day, respectively, with 8-week dose titration and 4-week maintenance (NCT03644264). Primary endpoint was non-inferiority analysis of change in sP from baseline to week 12. Secondary endpoints included sP over time and safety. RESULTS 415 patients were screened; 286 were enrolled and randomised (142 and 144 to SFOH and sevelamer, respectively). Mean (SD) baseline sP: 2.38 (0.57) and 2.38 (0.52) mmol/L, respectively. Mean (SD) change in sP from baseline to week 12: - 0.71 (0.60) versus -0.63 (0.52) mmol/L, respectively; difference (sevelamer minus SFOH) in least squares means (95% CI): 0.08 mmol/L (-0.02, 0.18) with the lower limit of 95% CI above the non-inferiority margin of -0.34 mmol/L. The SFOH group achieved target sP (1.13-1.78 mmol/L) earlier than the sevelamer group (56.5% vs. 32.8% at week 4) and with a lower pill burden (mean 3.7 vs. 9.1 tablets/day over 4 weeks of maintenance, respectively). Safety and tolerability of SFOH was consistent with previous studies, and no new safety signals were observed. CONCLUSION SFOH effectively reduced sP from baseline and was non-inferior to sevelamer after 12 weeks of treatment but had a lower pill burden in Chinese dialysis patients with hyperphosphataemia; SFOH benefit-risk profile is favourable in Chinese patients.
Collapse
Affiliation(s)
- Jun Liu
- NanFang Hospital of Southern Medical University, Guangzhou City, China
| | - Li Zuo
- Peking University People’s Hospital, Beijing, China
| | | | | | | | - Milica Enoiu
- Vifor Pharma Management Ltd., Glattbrugg, Switzerland
| |
Collapse
|
6
|
Teste M, Broutin A, Marty M, Valéra MC, Soares Cunha F, Noirrit-Esclassan E. Toothbrushing in children with autism spectrum disorders: qualitative analysis of parental difficulties and solutions in France. Eur Arch Paediatr Dent 2021; 22:1049-1056. [PMID: 34081310 DOI: 10.1007/s40368-021-00640-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2021] [Accepted: 05/24/2021] [Indexed: 11/28/2022]
Abstract
PURPOSE The oral care of a child with autism spectrum disorders (ASD) is a challenge, not only for dentists, but also for parents. The objective of this study was to evaluate the difficulties encountered by parents in maintaining oral hygiene in autistic children and the solutions they found to facilitate this daily act. METHODS A questionnaire with closed and open questions about characteristics of the child and oral health at home, conducted via Google Form, was sent to French families through 301 associations of parents with autistic children. For the quantitative analysis, logistic regression was used. The open answers were analysed by theme. RESULTS This study included 756 offspring aged 14.4 (± 8.1) years. Girls were 1.7 (95% CI: 1.1-2.8) times more likely to have toothbrushing difficulty than boys. Nonverbal patients (OR:3.2; 95% CI: 2.2-4.9), autistic patients (OR:2.8; 95% CI: 1.4-5.2), patients using pictograms (OR:1.6; 95% CI: 1.1-2.4), and younger children (OR:0.9; 95% CI: 0.9-0.9) were significantly more likely to encounter difficulties in tolerating toothbrushing. The qualitative analysis showed that parents used three main ways to facilitate toothbrushing: planning, modelling and making it enjoyable. Seventy-nine percent of parents did not feel sufficiently informed about the different oral hygiene prevention tools and techniques for their ASD children and would like to be educated in the daily management of oral hygiene. CONCLUSION The role of parents remains essential and professionals should work in collaboration with them.
Collapse
Affiliation(s)
- M Teste
- Pediatric Dentistry Department, Dental University, Université de Toulouse III, Toulouse, France
| | - A Broutin
- Pediatric Dentistry Department, Dental University, Université de Toulouse III, Toulouse, France
| | - M Marty
- Pediatric Dentistry Department, Dental University, Université de Toulouse III, Toulouse, France
| | - M C Valéra
- Children's Hospital Toulouse, Dental University, Université de Toulouse III, I2MC, Inserm U1048, CHU de Toulouse, Toulouse, France
| | - F Soares Cunha
- School of Physical Education, The Lifestyles and Health Research Group (GPES), University of Pernambuco, Recife, PE, Brazil.,Division of Orthodontics and Pediatric Dentistry, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - E Noirrit-Esclassan
- Children's Hospital Toulouse, Dental University, Université de Toulouse III, I2MC, Inserm U1048, CHU de Toulouse, Toulouse, France.
| |
Collapse
|
7
|
Abstract
INTRODUCTION Pediatric dentists sometimes have to care for children who refuse to cooperate with the oral examination or dental treatment. Behavior management strategies are used, such as "tell-show-do," distraction, and positive reinforcement. Anxiety management can also be performed by the use of conscious sedation (oral premedication, nitrous oxide/oxygen inhalation). Unfortunately, these techniques are sometimes insufficient for providing oral care, and protective stabilization may be an option in some situations. Little is known on the impact of physical restraint and how practitioners feel about it. The objective of this study was to evaluate the perception of dentists using protective stabilization for dental care in children. METHODS Semistructured qualitative interviews on the perception of pediatric dentists concerning protective stabilization were conducted in the pediatric dentistry department of the University Hospital of Toulouse, France. A thematic analysis of interview transcripts was provided via NVivo software. RESULTS This analysis highlighted 3 main themes. First, the perceptions of dentists concerning protective stabilization showed that this procedure has a major psychological impact and led to a feeling of professional failure. Second, the reasons for which the child was stabilized were described; these concerned the child (behavior, age, number of treatments) and the environment (the parents and the medical team). Finally, we detailed how dentists manage the effects of using of protective stabilization. CONCLUSION Dental surgeons must balance their requirement to make concrete decisions regarding the provision of care with their personal convictions about protective stabilization. This study also shows the need for specific training on this subject, as well as the desire of certain dentists that public authorities implement legislation on this matter. KNOWLEDGE TRANSFER STATEMENT The findings of this study will improve the management of young patients by identifying situations where protective stabilization may be useful (age of the child, diagnosis, protection of the child or the medical team), while showing its psychological impact on practitioners. Finally, this work provides a basis for decision makers to propose a framework for the use of physical restraint.
Collapse
Affiliation(s)
- M Marty
- Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
| | - A Marquet
- Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France
| | - M C Valéra
- Faculté de Chirurgie Dentaire, Université de Toulouse III, Toulouse, France.,Inserm, U1048 and Université Toulouse III, I2MC, Toulouse, France
| |
Collapse
|
8
|
Soussa RW, Woodward A, Marty M, Cannon CM. Breed is associated with the ABCB1-1Δ mutation in Australian dogs. Aust Vet J 2019; 98:79-83. [PMID: 31743433 DOI: 10.1111/avj.12896] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 10/18/2019] [Accepted: 10/29/2019] [Indexed: 11/29/2022]
Abstract
OBJECTIVE The ABCB1 gene encodes P-glycoprotein (P-gp), a cellular membrane pump. One functional mutation that leads to expression of a less functional form of P-gp, ABCB1-1Δ, has been described in dogs. Individuals with this mutation can have severe adverse reactions to common veterinary pharmaceuticals that are known substrates of this pump. We investigated the detection of this mutation in samples submitted to two Australian diagnostic laboratories. METHODS A total of 4842 dogs across 27 breeds were tested for the ABCB1-1Δ mutation from buccal swabs or EDTA blood using standard PCR, multiplex PCR, or genotyping chip. Statistical analysis was applied to determine the proportions and odds ratios of the ABCB1-1Δ mutation in herding breeds compared with non-herding breeds. RESULTS The ABCB1-1Δ mutation was detected in nine breeds. The most commonly affected breeds were collies, Australian shepherds, white Swiss shepherds, and Shetland sheepdogs. Of 32 dogs in 18 non-herding breeds tested, one cocker spaniel and one labradoodle were positive for the mutation, both heterozygous. CONCLUSION The most frequently affected breeds for ABCB1-1Δ mutation are the collie, Australian shepherd, white Swiss shepherd and Shetland sheepdog. As the mutation is associated with an increased incidence of adverse reactions to commonly used pharmaceuticals, veterinarians need to be aware of the breeds at most risk of carrying this mutation and consider testing these individuals prior to administering these medications.
Collapse
Affiliation(s)
- R W Soussa
- Internal Medicine Department, Southpaws Specialty Surgery for Animals, Moorabbin, Victoria, 3189, Australia
| | - A Woodward
- Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, Victoria, 3030, Australia
| | - M Marty
- Genetic Testing Division, Genomic Diagnostics, Heidelberg, Victoria, 3084, Australia
| | - C M Cannon
- Department of Veterinary Clinical Sciences, Melbourne Veterinary School, The University of Melbourne, Werribee, Victoria, 3030, Australia
| |
Collapse
|
9
|
Marty M, Nicolle P, Bataille S, Roudier-Daval C. Actions to improve chronic heart failure management in Paris and its suburbs, preliminary results. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Chronic Heart Failure treatment requires close collaboration between multiple health professionals (hospitals, general practitionners, cardiologists, nurses, pharmacists,...). Guidelines for management of chronic heart failure patients after hospitalization for heart failure were published in France in 2014.
In Paris and its suburbs (Ile de France) several indicators show that improvement of processes is required especially regarding linkage between hospital and ambulatory care (for example admission rate in emergency unit was 59,7% in 2014).
Actions
Since 2015 Regional Health Agency and Social Insurance have conducted several actions to improve patients care pathway: feed back to providers on their own results, support patients after hospital discharge, commitment of several hospitals to organize meetings with field professionals, setting up semi-urgent consultations in hospitals, bundled payment experience...
Preliminary Results
Indicators evolution from 2014 to 2017 is favorable for rate of admission in emergency unit (57,8% versus 59,7%), 6 months mortality (20,7% versus 23,1%), hospital readmission 6 months after index admission (24,4% versus 25,2%), but unfavorable for ambulatory clinical follow up rates (general practitionner consultation within fourteen days after hospital discharge (46,1% versus 52,5%), cardiologist consultation within sixty days after hospital discharge (47,1% versus 52,8%).
Conclusions
It is too early to assess the impact of each action and it will be difficult to conclude, because of interaction between actions. The evolution of outcome care indicators is satisfactory, which suggests the interest of acting on a whole care process. The worsening clinical follow up indicators leads to wonder about access to health care and requires an analysis by territory to adapt the actions.
Key messages
Actions to improve chronic heart failure management in Paris and its suburbs firsts outcomes are satisfactory. Acction adaptations are necessary and should be assessed in 2019/2020.
Collapse
Affiliation(s)
- M Marty
- Direction Régionale du Service Médical d’Ile de France, French National Health Insurance System, Paris, France
| | - P Nicolle
- Direction Régionale du Service Médical d’Ile de France, French National Health Insurance System, Paris, France
| | - S Bataille
- Direction de l’offre de Soins, Health Regional Agency, Paris, France
| | - C Roudier-Daval
- Direction de l’offre de Soins, Health Regional Agency, Paris, France
| |
Collapse
|
10
|
Segal D, Marty M, Gottschling J. PREDICTION OF SUICIDE IDEATION AMONG OLDER ADULTS: A TEST OF THE INTERPERSONAL-PSYCHOLOGICAL THEORY OF SUICIDE. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2595] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- D Segal
- University of Colorado Colorado Springs
| | - M Marty
- University of Colorado at Colorado Springs
| | | |
Collapse
|
11
|
Marty M, Gaye D, Perez P, Auder C, Nunes ML, Ferriere A, Haissaguerre M, Tabarin A. Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population. Eur J Endocrinol 2018; 178:439-446. [PMID: 29467231 DOI: 10.1530/eje-17-1056] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Accepted: 02/20/2018] [Indexed: 11/08/2022]
Abstract
CONTEXT The recent recommendations of the European Endocrine Society states that the performance of computed tomography (CT) to characterize 'true' adrenal incidentalomas (AIs) remains debatable. OBJECTIVE To determine relevant thresholds for usual CT parameters for the diagnosis of benign tumors using robust reference standard among a large series of 'true' AIs recruited in an endocrinological setting. DESIGN Retrospective study of 253 AIs in 233 consecutive patients explored in a single university hospital: 183 adenomas, 33 pheochromocytomas, 23 adrenocortical carcinomas, 5 other malignant tumors and 9 other benign tumors. Reference standard was histopathology in 118 AIs, biological diagnosis of pheochromocytoma in 2 AIs and size stability after at least 1 year of follow-up in 133 AIs. METHODS Sensitivity, specificity and positive and negative predictive values were estimated for various thresholds of size, unenhanced attenuation (UA), relative and absolute wash-out (RPW, APW) of contrast media. 197 scans were reviewed independently in a blinded fashion by two expert radiologists to assess inter-observer reproducibility of measurements. RESULTS Criteria associated with a 100% positive predictive value for the diagnosis of benign AI were: a combination of size and UA: 30 mm and 20 HU or 40 mm and 15 HU, respectively; RPW >53%; and APW >78%. Non-adenomatous AIs with rapid contrast wash-out were exclusively benign pseudocysts and pheochromocytomas, suggesting that classical thresholds of 60% and 40% for APW and RPW, respectively, can be safely used for patients with normal metanephrine values. Inter-observer reproducibility of all parameters was excellent (intra-class correlation coefficients: 0.96-0.99). CONCLUSIONS Our study, the largest conducted in AIs recruited in an endocrinological setting, suggests safe thresholds for quantitative CT parameters to avoid false diagnoses of benignity.
Collapse
Affiliation(s)
- M Marty
- Departments of EndocrinologyDiabetes and Nutrition
| | - D Gaye
- Departments of RadiologyCHU Haut-Leveque and University of Bordeaux, Bordeaux, France
| | - P Perez
- Public Health DepartmentClinical Epidemiology Unit INSERM, CIC 1401 and Bordeaux University Hospital, Bordeaux, France
| | - C Auder
- Departments of RadiologyCHU Haut-Leveque and University of Bordeaux, Bordeaux, France
| | - M L Nunes
- Departments of EndocrinologyDiabetes and Nutrition
| | - A Ferriere
- Departments of EndocrinologyDiabetes and Nutrition
| | | | - A Tabarin
- Departments of EndocrinologyDiabetes and Nutrition
| |
Collapse
|
12
|
Vilanova-Saingery C, Bailleul-Forestier I, Vaysse F, Vergnes JN, Marty M. Use and perception of nitrous oxide sedation by French dentists in private practice: a national survey. Eur Arch Paediatr Dent 2017; 18:385-391. [PMID: 29086891 DOI: 10.1007/s40368-017-0307-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 09/18/2017] [Indexed: 11/29/2022]
Abstract
AIM The aim of this national survey was to record the use of nitrous oxide and the perceptions of French dental practitioners to this form of sedation. The use of nitrous oxide sedation (NOS) has been authorised in private dental practice in France since December 2009 but, to date, no study implementing both quantitative and qualitative methods has explored such use. METHODS The data were collected using a Google Forms questionnaire. A mixed methodology was used for data analysis: a quantitative approach to explore the use of conscious sedation and a qualitative thematic approach (using Nvivo software) to determine the practitioner's perception of it. RESULTS Responses were collected from 225 practitioners (19% of the target population of 1185). Most of the responders were trained in NOS use in private dental clinics. Seventy-three percent of those who trained privately actually used NOS, compared to 53% of those trained at university (p-value = 0.0052). Above all, NOS was used for children requiring restorative dentistry. The average price of the sedation was 50 Euros and it lasted, on average, for 37 min. The qualitative and thematic analysis revealed the financial and technical difficulties of implementing NOS in private practice. However, it also showed the benefits and pleasure associated with NOS use. CONCLUSION This statistical survey of French dental practitioners offers an insight of the current state of the use of conscious sedation with nitrous oxide in private general dental practice in France. It also includes the first report of dental practitioners' perceptions of NOS use and may lead to a better understanding of the reasons why sedation is sometimes not used in private practice.
Collapse
Affiliation(s)
- C Vilanova-Saingery
- Perpignan Saint Jean Hospital, Paul Sabatier University, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - I Bailleul-Forestier
- Rangueil Teaching Hospital, Paul Sabatier University, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - F Vaysse
- Rangueil Teaching Hospital, Paul Sabatier University, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - J-N Vergnes
- Rangueil Teaching Hospital, Paul Sabatier University, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - M Marty
- Rangueil Teaching Hospital, Paul Sabatier University, Toulouse, France. .,LIRDEF, Montpellier III University, Montpellier, France. .,Dental Faculty, 3 Chemin des maraîchers, 31400, Toulouse, France.
| |
Collapse
|
13
|
Meaume S, Marty M, Colin D. Prospective observational study of single- or multi-compartment pressure ulcer prevention cushions: PRESCAROH project. J Wound Care 2017; 26:537-544. [DOI: 10.12968/jowc.2017.26.9.537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Meaume
- Rothschild Hospital – Geriatric Department and Wound Care Unit, Assistance Publique hôpitaux de Paris, Paris, France
| | - M. Marty
- Nukleus, Clinical Research Department, Paris, France
| | - D. Colin
- Centre de l'Arche, Saint-Saturnin, France
| |
Collapse
|
14
|
Marty M, Noirrit-Esclassan E, Diemer F. Arsenic trioxide-induced osteo-necrosis treatment in a child: mini-review and case report. Eur Arch Paediatr Dent 2016; 17:419-422. [PMID: 27613404 DOI: 10.1007/s40368-016-0250-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 07/14/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Arsenic oxide compounds were traditionally used as devitalizing agents. Due to its toxicity, leakage of such compounds into the periodontium can cause gingival and osteo-necrosis. Their use is forbidden in Europe and the USA for decades, however, some dentists seem to still use it. CASE REPORT We report the case of a 14-year-old girl referred to the paediatric dentistry department of Toulouse University hospital, France, presenting a bone necrosis following the use of an arsenic trioxide product to accelerate pulp necrosis. TREATMENT The treatment included surgical removal of necrosis bone sequestrum, complete pulpectomy and an intermediate restoration of the tooth 27. FOLLOW-UP After 1 week, the clinical conditions greatly improved. A restoration using a ceramic crown was performed after 2 months, and complete healing was observed after 1 year follow-up. CONCLUSION Although arsenic trioxide is neither appropriate nor permitted for use in modern dentistry, especially in paediatric dentistry, some rare cases of arsenic-induced osteo-necrosis can still be encountered. A clearer message must be given to all dental practitioners against the use of arsenic trioxide in modern endodontic treatment.
Collapse
Affiliation(s)
- M Marty
- Department of Pediatric Dentistry, Faculté de Chirurgie-dentaire, Toulouse Dental School, University of Toulouse III, 3 chemin des Maraîchers, 31069, Toulouse, France.
| | - E Noirrit-Esclassan
- Department of Pediatric Dentistry, Faculté de Chirurgie-dentaire, Toulouse Dental School, University of Toulouse III, 3 chemin des Maraîchers, 31069, Toulouse, France
| | - F Diemer
- Department of Endodontics, Faculté de Chirurgie-dentaire, Toulouse Dental School, University of Toulouse III, 3 chemin des Maraîchers, 31069, Toulouse, France
| |
Collapse
|
15
|
Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P. BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2016; 159:499-511. [PMID: 27592112 DOI: 10.1007/s10549-016-3961-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 08/25/2016] [Indexed: 12/18/2022]
Abstract
PURPOSE Neoadjuvant systemic therapy (NAC) is currently used in the treatment of stage II/III breast cancer. Pathological complete response as a surrogate endpoint for clinical outcomes is not completely validated for all subgroups of breast cancers. Therefore, there is a need for reliable predictive tests of the most effective treatment. METHODS We used a combination of predictive clinical, pathological, and gene expression-based markers of response to NAC in a prospective phase II multicentre randomized clinical trial in breast cancer patients, with a long follow-up (8 years). This study concerned the subpopulation of 188 patients with similar levels of pathological response rates to sequential epirubicin/cyclophosphamide and docetaxel to determine predictive marker of pCR and DFS. We used a set of 45 genes selected from high throughput analysis and a standardized RT-qPCR. We analyzed the predictive markers of pathological complete response (pCR) and DFS in the overall population and DFS the subpopulation of 159 patients with no pCR. RESULTS In the overall population, combining both clinical and genomic variables, large tumor size, low TFF1, and MYBL2 overexpression were significantly associated with pCR. T4 Stage, lymphovascular invasion, negative PR status, histological type, and high values of CCNB1 were associated with DFS. In the no pCR population, only lymphovascular invasion and high values of BIRC5 were associated with DFS. CONCLUSIONS We confirm the importance of ER-related and proliferation genes in the prediction of pCR in NAC-treated breast cancer patients. Furthermore, we identified BIRC5 (survivin) as a main pejorative prognostic factor in patients with breast cancers with no pCR. These results also open perspective for predictive markers of new targeted therapies.
Collapse
Affiliation(s)
- A S Hamy
- Department of Biostatistics, Institut Curie, Paris, France
| | - I Bieche
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France
| | - J Lehmann-Che
- APHP Molecular Oncology Unit, Hôpital Saint Louis, Paris Diderot University, 1 Avenue Claude Vellefaux, 75010, Paris, France
| | - V Scott
- Biology Department, Institut Gustave Roussy, Villejuif, France
| | - Ph Bertheau
- APHP Pathology Department, Hôpital Saint Louis, Paris Diderot University, Paris, France
| | - J M Guinebretière
- Pathology Department, Hôpital René-Huguenin, Institut Curie, Saint-Cloud, France
| | - M C Matthieu
- Pathology Department, Institut Gustave Roussy, Villejuif, France
| | | | - O Tembo
- APHP, Centre for Therapeutic Innovation, Saint-Louis Hospital, Paris, France
| | - M Marty
- APHP, Centre for Therapeutic Innovation, Saint-Louis Hospital, Paris, France
| | - B Asselain
- Department of Biostatistics, Institut Curie, Paris, France
| | - F Spyratos
- Pharmacogenomics Unit, Department of Genetics, Institut Curie, Paris, France
| | - P de Cremoux
- APHP Molecular Oncology Unit, Hôpital Saint Louis, Paris Diderot University, 1 Avenue Claude Vellefaux, 75010, Paris, France.
| |
Collapse
|
16
|
Affiliation(s)
- M. Marty
- Toulouse Dental School, Department of Pediatric Dentistry, Toulouse III University, Toulouse, France
- Master 2REFE-Mindful Management and Emotional Capital under the responsibility of Pr. Benedicte Gendron, University Paul Valery Montpellier 3, Montpellier, France
| |
Collapse
|
17
|
Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol 2016; 27:1029-1034. [PMID: 26961151 DOI: 10.1093/annonc/mdw132] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 03/03/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The gold standard end point in randomized clinical trials in metastatic breast cancer (MBC) is overall survival (OS). Although therapeutics have been approved based on progression-free survival (PFS), its use as a primary end point is controversial. We aimed to assess to what extent PFS may be used as a surrogate for OS in randomized trials of anti-HER2 agents in HER2+ MBC. METHODS Eligible trials accrued HER2+ MBC patients in 1992-2008. A correlation approach was used: at the individual level, to estimate the association between investigator-assessed PFS and OS using a bivariate model and at the trial level, to estimate the association between treatment effects on PFS and OS. Correlation values close to 1.0 would indicate strong surrogacy. RESULTS We identified 2545 eligible patients in 13 randomized trials testing trastuzumab or lapatinib. We collected individual patient data from 1963 patients and retained 1839 patients from 9 trials for analysis (7 first-line trials). During follow-up, 1072 deaths and 1462 progression or deaths occurred. The median survival time was 22 months [95% confidence interval (CI) 21-23 months] and the median PFS was 5.7 months (95% CI 5.5-6.1 months). At the individual level, the Spearman correlation was equal to ρ = 0.67 (95% CI 0.66-0.67) corresponding to a squared correlation value of 0.45. At the trial level, the squared correlation between treatment effects (log hazard ratios) on PFS and OS was provided by R(2) = 0.51 (95% CI 0.22-0.81). CONCLUSIONS In trials of HER2-targeted agents in HER2+ MBC, PFS moderately correlates with OS at the individual level and treatment effects on PFS correlate moderately with those on overall mortality, providing only modest support for considering PFS as a surrogate. PFS does not completely substitute for OS in this setting.
Collapse
Affiliation(s)
- S Michiels
- Unit of Biostatistics and Epidemiology, Gustave Roussy, Villejuif; University Paris-Sud, University Paris-Saclay, UVSQ, CESP, INSERM, Villejuif; Plateform Ligue nationale contre le cancer for meta-analyses in oncology, Gustave Roussy, Villejuif, France; Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
| | - L Pugliano
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels; Breast International Group (BIG), Brussels, Belgium
| | - S Marguet
- Unit of Biostatistics and Epidemiology, Gustave Roussy, Villejuif
| | - D Grun
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels
| | - J Barinoff
- Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany
| | - D Cameron
- Department of Oncology, University of Edinburgh, Edinburgh, UK
| | - M Cobleigh
- Rush University Medical Center, Chicago, USA
| | - A Di Leo
- Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
| | - S Johnston
- Breast Unit, Royal Marsden Hospital, London, UK
| | - G Gasparini
- Scientific Direction, IRCCS National Cancer Research Centre "Giovanni Paolo II,"Bari, Italy
| | - B Kaufman
- The Institute of Breast Oncology, Sheba Medical Center, Tel Hashomer, Israel
| | - M Marty
- Breast Cancer Diseases Unit and Department of Medical Oncology, Saint Louis Hospital, APHP, Paris, France
| | - V Nekljudova
- German Breast Group, GBG ForschungsGmbH, Neu-Isenburg, Germany
| | - S Paluch-Shimon
- The Institute of Breast Oncology, Sheba Medical Center, Tel Hashomer, Israel
| | - F Penault-Llorca
- Department of Pathology, Centre Jean Perrin, EA 4233, University of Auvergne, Clermont-Ferrand, France
| | - D Slamon
- Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles
| | - C Vogel
- University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, Columbia Cancer Research Network of Florida, Miami, USA
| | - G von Minckwitz
- German Breast Group, GBG ForschungsGmbH, Neu-Isenburg, Germany
| | - M Buyse
- IDDI, Louvain-la-Neuve, Hasselt University, Hasselt, Belgium
| | - M Piccart
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels; Breast International Group (BIG), Brussels, Belgium
| |
Collapse
|
18
|
Giacchetti S, De Roquancourt A, Groheux D, Piron P, Lehmann-che J, Cuvier C, Resche-rigon M, Albiter M, Roche B, Frank S, Hamy AS, Teixeira L, Marty M, Lalloum M, Espié M. Abstract P1-14-08: Prediction of pathological response (pCR) to neoadjuvant dose dense and intense cyclophosphamide and anthracycline in a prospective series of triple negative locally advanced breast cancers (TNLABC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Stage II-III TNBC retains a poor outcome despite high chemosensitivity. Patients (pts) with pCR after neoadjuvant chemotherapy have a good prognosis whereas non-responding pts have a 25-40% risk of distant relapse at 5 years. pCR is thus a major goal in TNBC. We previously reported that TNLABC benefit the most of dose dense dose intense cyclophosphamide (C)-epirubicin (E) (S.Giacchetti; BJC, 2014)
Aim: To confirm these results prospectively and analyze the predictive factors of response to high dose chemotherapy in TNBC.
Patients and methods: From january 2009 to april 2015 non inflammatory TNLABC received high dose C (1200 mg/m2 d1 qw 2) with E (75 mg/m2/ d1 qw2) for 6 cycles. The pts had a breast biopsy with frozen tissue. We performed molecular studies: qRT-PCR for AR, FOXA1, PI3K and FASAY technic for p53 mutation.The percentage of stromal Tumor-infiltrating lymphocytes (TILs) was also evaluated by two independent pathologists and assessed as a continuous variable. A18F-FDG PET/CT was performed initially and after 2 courses of chemotherapy and the metabolic answer assessed as a variation of the tumor uptake (ΔSUVmax). We report here the pathological complete response (pCR) (absence of infiltrative carcinomas in the breast and in the lymph nodes) and the factors associated with pCR.
Results: The characteristics of the 74 pts are listed in table 1. The median age is 48 years old, 48 pts (65.8%) are premenopausal and 79% did not have any family history of breast cancers. TIL was divided in 3 groups < 10 % (26 pts, 40 %); 10-50 % (30 pts, 46 %) > 50% (9 pts, 14 %). Pathological response was assessed in 66 pts, one pt progressed during chemotherapy and 6 pts did not undergo surgery yet. 28 pts were in pCR (42.4 %). With a median follow up of 25 months, 13 pts (17.8 %) progressed and 8 (11%) died.
Table 1: Patients characteristics and pCR according to tumor features and metabolic responseCharacteristicsNumber of pts (%)N of pts evaluated for pCRpCR (%)OR [IC 95%]p-valueTumor size T2363519 (54)10.04T337319 (29)0.34 [0.12 ; 0.96]Nodal status N0363315 (46)10.62N1/N2/N3 24/11/33313 (39)0.78 [0.29 ; 2.07]Histological grade: 2660 (0) 0.04*3676028 (47)TILs <10 %26 (40)2510 (40)10.02610-50 %30 (46)267 (27)0.55 [0.17 ; 1.80]≥ 509 (14)9 7 (78)5.25 [0.90 ; 30.62]P53 Mutated54 (89)5121 (41)10.43WT7 (12)53 (60)2.14 [0.33; 13.96]AR Negative43 (83)4318 (42)10.46Positive 9 (17)95 (56)1.74 [0.41 ; 7.38]FOXA1 Negative40 (77)4015 (38)10.08Positive 12 (23)128 (60) 3.33 [0.86 ; 12.99]Molecular Apocrine8 (17)85 (63)10.19TN38 (83)3814 (37)0.35 [0.07 ; 1.69]PI3K Non mutated44 (88)4419 (43)10.75Mutated6 (12)63 (50)1.31 [0.24 ; 7.26]SUVmax at 2 courses0.0001< 70 %27 (53)221 (5)1≥ 70 %24 (47)2318 (78)79.2 [8.48 ; 739.82]* Measured with a Fisher Test
Tumor size, tumor grade, percentage of TILs, the change in 18F-fluorodeoxyglucose tumor uptake (ΔSUVmax) were significantly associated with pCR at univariate analysis. Only one factor remained significant at multivariate analysis, the ΔSUVmax, OR: 0.04 [0.007- 0.27], p = 0.0008.
Conclusion: In this prospective phase III trial we confirm the efficacy of a dose dense EC in TNBC. The metabolic response evaluated with 18 F-FDG PET/CT is a strong and reliable predictor of pCR and could allow an early change of treatment for the non responders. A clinical trial is planned to test this strategy.
Citation Format: Giacchetti S, De Roquancourt A, Groheux D, Piron P, Lehmann-che J, Cuvier C, Resche-rigon M, Albiter M, Roche B, Frank S, Hamy A-S, Teixeira L, Marty M, Lalloum M, Espié M. Prediction of pathological response (pCR) to neoadjuvant dose dense and intense cyclophosphamide and anthracycline in a prospective series of triple negative locally advanced breast cancers (TNLABC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-08.
Collapse
Affiliation(s)
- S Giacchetti
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - A De Roquancourt
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - D Groheux
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - P Piron
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - J Lehmann-che
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - C Cuvier
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - M Resche-rigon
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - M Albiter
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - B Roche
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - S Frank
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - A-S Hamy
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - L Teixeira
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - M Marty
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - M Lalloum
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| | - M Espié
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Hôpital Saint Louis, Paris, France; Biochemistry Department, Paris, France; Department of Biostatistics, Paris, France; Department of Radiology, Paris, France; Institut Curie, Paris, France
| |
Collapse
|
19
|
Giacchetti S, Hamy-Petit AS, Delaloge S, Brain E, Berger F, Mathieu MC, de Cremoux P, Bertheau P, Guinebretière JM, Saghatchian M, Tembo O, Marty M, Pierga JY. Abstract P1-14-09: Long term survival of locally advanced breast cancers (LABC) treated with neoadjuvant treatment, results of a multicenter randomised phase II study (Remagus 02 trial). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Backgound : The primary analysis of the REMAGUS-02 multicenter randomized phase II trial demonstrated that celecoxib did not improve pCR rates in pts with HER2-negative localized invasive breast cancer (BC), whereas trastuzumab increased pCR rates in HER2-positive ones [Pierga BCRT 2010]. We report here the long-term follow-up results of this trial for disease free survival (DFS) and overall survival (OS).
Patients and methods: From May 2004 to October 2007, 340 stage II-III BC patients were randomly assigned to receive 4 cycles (c) of epirubicin–cyclophosphamide q 3 w followed by 4 c of docetaxel q 3 w +/- trastuzumab in HER2 positive pts (120 pts) or +/- celecoxib in HER2 negative pts (n=220). From September 2005, all pts with HER2 positive BC received adjuvant T for a total of 18 c (n=106). Patients with hormone receptors (HR) positive tumor received adjuvant endocrine treatment according to menopausal status
Results: With a median follow up of nearly 8 years (94.4 months, 20-127m), 112 relapses and 75 deaths have been observed (median DFS and OS not reached). Eight years DFS and OS were respectively 63 % [57%-71%] and 75 % [70%-81%] in HER2 negative group; and 75% [67%-83%] and 82 % [74%-90%] in HER2 positive group. DFS was significantly higher in HER+ pts than in HER2-(HR: 0.64 [0.42-0.99], p=0.042), whereas OS did not differ significantly (HR: 0.67, [0.41-1.11], p=0.123).
In the overall population, progesterone receptor (PgR) positivity was associated with a better DFS (p=0.012) and OS (p<0.001) as compared to ER+/PgR- (DFS: HR=2.07 [1.27-3.39]; OS: HR=2.53 [1.3-4.92]) and ER-/PR-; DFS: HR=1.56 [0.98-2.46]; OS: HR: 3.34 [1.87 – 5.97]. In the ER-/PR- group, DFS reached a "plateau" after three years follow-up, while the annual risk of relapse remained constant in the ER+/PR- subgroup.
In the HER2- subgroup, no effect of neoadjuvant celocoxib was observed on survival, neither in intention to treat (ITT) nor in per protocol analyses. In the multivariate analysis clinical stage (T3/T4 versus T2, HR: 1.92 [1.209 - 3.05], p=0.006), PgR status (positive versus negative HR : 0.52, [0.32-0.84], p=0.007) and pCR (yes vs no, HR : 0.213 [0.066-0.687], p=0.01) were significant predictors of DFS.
In the HER2+ subgroup, neoadjuvant versus adjuvant trastuzumab was not significantly associated with DFS, neither in the ITT, nor in the per protocol analysis.
Conclusion: Celecoxib was not associated with pCR or survival benefit when added to conventional neoadjuvant CT in Her2-negative BC pts. Lack of PgR expression is a major prognostic factor for survival. Neoadjuvant versus adjuvant trastuzumab increased pCR rates but did not change significantly DFS and OS of HER2 positive BC pts.
Citation Format: Giacchetti S, Hamy-Petit A-S, Delaloge S, Brain E, Berger F, Mathieu M-C, de Cremoux P, Bertheau P, Guinebretière J-M, Saghatchian M, Tembo O, Marty M, Pierga J-Y. Long term survival of locally advanced breast cancers (LABC) treated with neoadjuvant treatment, results of a multicenter randomised phase II study (Remagus 02 trial). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-09.
Collapse
Affiliation(s)
- S Giacchetti
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - A-S Hamy-Petit
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - S Delaloge
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - E Brain
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - F Berger
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - M-C Mathieu
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - P de Cremoux
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - P Bertheau
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - J-M Guinebretière
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - M Saghatchian
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - O Tembo
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - M Marty
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| | - J-Y Pierga
- Breast Disease Unit, Hôpital Saint Louis, Paris, France; Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Biostatistics Department, Paris, France; Hôpital Saint Louis, APHP, Paris, France; Molecular oncology, Hôpital Saint Louis, APHP, Paris, France; CITOH, Hôpital Saint Louis, Paris, France
| |
Collapse
|
20
|
Demoulin C, Roussel N, Marty M, Mathy C, Genevay S, Henrotin Y, Tomasella M, Mahieu G, Vanderthommen M. [THE MALADAPTIVE BELIEFS OF PATIENTS WITH LOW BACK PAIN. A NARRATIVE REVIEW]. Rev Med Liege 2016; 71:40-46. [PMID: 26983313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE to summarize the knowledge regarding the maladaptive beliefs of patients with non-specific low back pain. METHODS a narrative literature review on these beliefs was conducted by an international and multidisciplinary team of experts in the field. RESULTS these beliefs, which can result in negative consequences on functioning and on patient prognosis, have various origins: family and friends, media, previous experience and/or health care professionals' messages. The latter, who have a considerable and enduring influence, have the potential to change and correct the patients' misbeliefs; however, they can also reinforce them in case of inappropriate messages and attitudes. Informing and educating the patient (by means of reassurance, explanations of the non-systematic association pain-injury, encouragement to get and stay physically active) are the basis of treatment. Taking into account the consequences of some words which may be misinterpreted, the results of imaging should be wisely discussed with the patient. Pain neurophysiology education and cognitive behavioral therapy (i.a., in vivo graded exposure techniques) are effective additional treatments. CONCLUSIONS Misbeliefs are frequent in patient with low back pain. They do need to be looked for and corrected.
Collapse
|
21
|
Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. Leuk Lymphoma 2015; 57:852-65. [PMID: 26308278 DOI: 10.3109/10428194.2015.1085528] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Emergence of new agents has deeply modified treatment options and the role of chlorambucil (CLB) in B-cell malignancies. We conducted a systematic review of prospective, randomized, controlled trials (RCTs) investigating the benefits and harms of CLB used alone or in combination with other treatment in patients suffering from chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM). For CLL, review of the nine RCTs showed that the main advantage of CLB is its low toxicity in comparison with purine nucleoside analogs like fludarabine in either CLL or NHL. In CLL, the major disadvantage is the very low rate of complete response, except when combining an anti-CD20 antibody. For B-cell lymphoma and WM, six RCTs were summarized. Results according to the usual criteria are presented and the role of CLB, used mostly in combination with an anti-CD20 antibody, is discussed for each indication, in particular for unfit patients.
Collapse
Affiliation(s)
- Stéphane Lepretre
- a Service d'hématologie, centre de lutte contre le cancer, Henri Becquerel , Rouen , France
| | - C Dartigeas
- b Service de cancérologie et d'hématologie thérapie cellulaire, CHU Bretonneau , Tours , France
| | - P Feugier
- c Service hématologie, CHU Nancy Brabois, Vandoeuvre Les Nancy , Nancy , France
| | - M Marty
- d Nukleus, département recherche clinique , Paris , France , and
| | - G Salles
- e Service d'hématologie, Hospices civils de Lyon, Centre hospitalier Lyon Sud , Lyon , France
| |
Collapse
|
22
|
Affiliation(s)
- S. Meaume
- Rothschild Hos pital– Geriatric Department and Wound Care Unit, Assistance publique hôpitaux de Paris, Paris, France
| | - M. Marty
- Nukleus, Clinical Research Department, Paris, France
| |
Collapse
|
23
|
Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, DeSilvio M, Lau MR, Kothari D, Koch KM, Diéras V. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann Oncol 2014; 24:2005-11. [PMID: 23878115 DOI: 10.1093/annonc/mdt222] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND This phase IB, open-label, dose-escalation study evaluated the safety, tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with docetaxel and trastuzumab in patients with previously untreated stage IV metastatic breast cancer (MBC) tumors overexpressing human epidermal growth factor receptor 2 (HER2). PATIENTS AND METHODS Evaluated dose regimens included lapatinib (500-1500 mg/day), docetaxel (triweekly; 60-100 mg/m²), and trastuzumab (weekly; 2 mg/kg fixed dose); prophylactic granulocyte colony-stimulating factor was included with regimens with ≥750 mg/day lapatinib. End points included OTR and safety/tolerability (primary), overall response rate (ORR), and pharmacokinetics (secondary). RESULTS None of the patients (N = 53) experienced dose-limiting toxic effects (DLTs) at the highest dose level; thus, the OTR of lapatinib with 100 mg/m(2) docetaxel was not determined. Common adverse events included diarrhea, nausea, alopecia, fatigue, and rash; grade 3/4 (≥2 patients) were neutropenia, diarrhea, leukopenia, peripheral neuropathy, and rash. Seven patients had DLTs (cycle 1). In 45 patients with measurable disease confirmed by bone scan, investigator-assessed ORR was 31%; without bone scan, confirmation was 64%; 8 patients without measurable disease were evaluated as stable. Lapatinib/docetaxel plasma concentrations were positively associated with complete response. CONCLUSIONS Lapatinib/docetaxel/trastuzumab is a feasible and well-tolerated treatment of untreated HER2-positive stage IV MBC. Two lapatinib/docetaxel OTR doses were recommended (1250 mg/75 mg/m²; 1000 mg/100 mg/m²). CLINICAL TRIAL NUMBER NCT00251433.
Collapse
Affiliation(s)
- J Crown
- All Ireland Cooperative Oncology Research Group, Dublin, Ireland.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC. Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. Ann Oncol 2014; 25:773-780. [PMID: 24351401 DOI: 10.1093/annonc/mdt531] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.
Collapse
Affiliation(s)
- R Bartsch
- Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - S Frings
- Hoffmann-La Roche, Basel, Switzerland
| | - M Marty
- Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, Paris, France
| | - A Awada
- Institut Jules Bordet/Medical Oncology Clinic, Université Libre de Bruxelles, Brussels, Belgium
| | - A S Berghoff
- Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
| | - P Conte
- Department of Surgery/Oncology and Gastroenterology, University of Padova, Padova, Italy
| | - S Dickin
- Eli-Lilly and Company, Basingstoke, UK
| | - H Enzmann
- BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
| | - M Gnant
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria; Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - M Hasmann
- Roche Diagnostics GmbH, pRED Penzberg, Penzberg, Germany
| | - H R Hendriks
- Hendriks Pharmaceutical Consulting, Purmerend, The Netherlands
| | - A Llombart
- Medical Oncology Department, Arnau Vilanova Hospital, Valencia, Spain
| | | | - G von Minckwitz
- German Breast Group, Neu-Isenburg; University Women's Hospital Frankfurt, Frankfurt, Germany
| | - F Penault-Llorca
- Department of Pathology, Centre Jean-Perrin, Clermont-Ferrand; Department of Pathology, University of Auvergne, Clermont-Ferrand, France
| | - M Scaltriti
- Human Oncology & Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, USA
| | - Y Yarden
- Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
| | - H Zwierzina
- Medical University of Innsbruck, Innsbruck, Austria
| | - C C Zielinski
- Clinical Division of Oncology/Department of Medicine I; Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
25
|
Feldis M, Dilly M, Marty M, Laurent F, Cassinotto C. An inflammatory fibroid polyp responsible for an ileal intussusception discovered on an MRI. Diagn Interv Imaging 2014; 96:89-92. [PMID: 24618561 DOI: 10.1016/j.diii.2014.01.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- M Feldis
- Diagnostic and Interventional Radiology Department, Hôpital du Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, 1, avenue de Magellan, 33604 Pessac cedex, France.
| | - M Dilly
- Department of Pathological Anatomy, Hôpital du Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, 1, avenue de Magellan, 33604 Pessac cedex, France
| | - M Marty
- Department of Pathological Anatomy, Hôpital du Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, 1, avenue de Magellan, 33604 Pessac cedex, France
| | - F Laurent
- Diagnostic and Interventional Radiology Department, Hôpital du Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, 1, avenue de Magellan, 33604 Pessac cedex, France
| | - C Cassinotto
- Diagnostic and Interventional Radiology Department, Hôpital du Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, 1, avenue de Magellan, 33604 Pessac cedex, France
| |
Collapse
|
26
|
Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. Br J Cancer 2014; 110:1413-9. [PMID: 24569467 PMCID: PMC3960631 DOI: 10.1038/bjc.2014.81] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Revised: 01/14/2014] [Accepted: 01/20/2014] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Triple-negative (TN) breast cancers exhibit major initial responses to neoadjuvant chemotherapy, but generally have a poor outcome. Because of the lack of validated drug targets, chemotherapy remains an important therapeutic tool in these cancers. METHODS We report the survival of two consecutive series of 267 locally advanced breast cancers (LABC) treated with two different neoadjuvant regimens, either a dose-dense and dose-intense cyclophosphamide-anthracycline (AC) association (historically called SIM) or a conventional sequential association of cyclophosphamide and anthracycline, followed by taxanes (EC-T). We compared pathological responses and survival rates of these two groups and studied their association with tumours features. RESULTS Although the two regimens showed equivalent pathological complete response (pCR) in the whole population (16 and 12%), the SIM regimen yielded a non-statistically higher pCR rate than EC-T (48% vs 24%, P=0.087) in TN tumours. In the SIM protocol, DFS was statistically higher for TN than for non-TN patients (P=0.019), although we showed that the TN status was associated with an increased initial risk of recurrence in both regimens. This effect gradually decreased and after 2 years, TN was associated with a significantly decreased likelihood of relapse in SIM-treated LABC (hazard ratio (HR)=0.25 (95% CI: 0.07-0.86), P=0.028). CONCLUSIONS AC dose intensification treatment is associated with a very favourable long-term survival rate in TN breast cancers. These observations call for a prospective assessment of such dose-intense AC-based regimens in locally advanced TN tumours.
Collapse
Affiliation(s)
- S Giacchetti
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - R Porcher
- AP-HP, Hôpital Saint-Louis, Biostatistic Department, Paris 75475, France
| | - J Lehmann-Che
- 1] AP-HP, Hôpital Saint-Louis, Molecular Biology Department, Paris 75475, France [2] INSERM/CNRS/University Paris Diderot UMR 944/7212, Paris 75475, France
| | - A-S Hamy
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - A de Roquancourt
- 1] AP-HP, Hôpital Saint-Louis, Pathology Department, Paris 75475, France [2] University Paris Diderot, UMR-S-728 INSERM, Paris 75475, France
| | - C Cuvier
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - P-H Cottu
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - P Bertheau
- 1] AP-HP, Hôpital Saint-Louis, Pathology Department, Paris 75475, France [2] University Paris Diderot, UMR-S-728 INSERM, Paris 75475, France
| | - M Albiter
- AP-HP, Hôpital Saint-Louis, Radiology Department, Paris 75475, France
| | - F Bouhidel
- 1] AP-HP, Hôpital Saint-Louis, Pathology Department, Paris 75475, France [2] University Paris Diderot, UMR-S-728 INSERM, Paris 75475, France
| | - F Coussy
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - J-M Extra
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - M Marty
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| | - H de Thé
- 1] AP-HP, Hôpital Saint-Louis, Molecular Biology Department, Paris 75475, France [2] INSERM/CNRS/University Paris Diderot UMR 944/7212, Paris 75475, France
| | - M Espié
- AP-HP, Hôpital Saint-Louis, Breast Disease Unit, University Paris Diderot, Paris 75475, France
| |
Collapse
|
27
|
Mathy C, Marty M, Cedraschi C, Genevay S, Laroche F, Duplan B, Savarieau B, Broonen JP, Henrotin Y. Development and validation of the VEBI (Volitionnal Exercice Back Inentory) to enhance the performance of physical exercises in chronic low back pain patients. Ann Phys Rehabil Med 2013. [DOI: 10.1016/j.rehab.2013.07.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Mathy C, Marty M, Cedraschi C, Genevay S, Laroche F, Duplan B, Savarieau B, Broonen JP, Henrotin Y. Développement et validation de l’Inventaire volitionnel des exercices du dos (IVE) pour augmenter la pratique d’exercices physiques chez le patient lombalgique chronique. Ann Phys Rehabil Med 2013. [DOI: 10.1016/j.rehab.2013.07.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Feldis M, Marty M, Dilly M, Laurent F, Chiche L, Cassinotto C. Pancreatic serous cystadenoma with signs of compression. Diagn Interv Imaging 2013; 94:905-8. [DOI: 10.1016/j.diii.2013.04.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
30
|
Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer 2013; 109:1157-64. [PMID: 23942075 PMCID: PMC3778311 DOI: 10.1038/bjc.2013.469] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2013] [Revised: 07/17/2013] [Accepted: 07/21/2013] [Indexed: 12/17/2022] Open
Abstract
Background: Pathologic complete response (pCR) to neoadjuvant treatment (NAT) is associated with improved survival of patients with HER2+ breast cancer. We investigated the ability of interim positron emission tomography (PET) regarding early prediction of pathology outcomes. Methods: During 61 months, consecutive patients with locally advanced or large HER2+ breast cancer patients without distant metastases were included. All patients received NAT with four cycles of epirubicin+cyclophosphamide, followed by four cycles of docetaxel+trastuzumab. 18F-fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) was performed at baseline (PET1) and after two cycles of chemotherapy (PET2). Maximum standardised uptake values were measured in the primary tumour as well as in the axillary lymph nodes. The correlation between pathologic response and SUV parameters (SUVmax at PET1, PET2 and ΔSUVmax) was examined with the t-test. The predictive performance regarding the identification of non-responders was evaluated using receiver operating characteristics (ROC) analysis. Results: Thirty women were prospectively included and 60 PET/CT examination performed. At baseline, 22 patients had PET+ axilla and in nine of them 18F-FDG uptake was higher than in the primary tumour. At surgery, 14 patients (47%) showed residual tumour (non-pCR), whereas 16 (53%) reached pCR. Best prediction was obtained when considering the absolute residual SUVmax value at PET2 (AUC=0.91) vs 0.67 for SUVmax at PET1 and 0.86 for ΔSUVmax. The risk of non-pCR was 92.3% in patients with any site of residual uptake >3 at PET2, no matter whether in breast or axilla, vs 11.8% in patients with uptake ⩽3 (P=0.0001). The sensitivity, specificity, PPV, NPV and overall accuracy of this cutoff were, respectively: 85.7%, 93.8%, 92.3%, 88.2% and 90%. Conclusion: The level of residual 18F-FDG uptake after two cycles of chemotherapy predicts residual disease at completion of NAT with chemotherapy+trastuzumab with high accuracy. Because many innovative therapeutic strategies are now available (e.g., addition of a second HER2-directed therapy or an antiangiogenic), early prediction of poor response is critical.
Collapse
Affiliation(s)
- D Groheux
- Nuclear Medicine, Saint-Louis Hospital, 1 avenue Claude Vellefaux, Paris 75475, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Chevalier X, Richette P, Rannou F, Avouac B, Dapoigny M, Ducrotte P, Jean Louis D, Savarieau B, Blanc D, Marty M. SAT0338 Tolerance and efficacy of a new formulation of diacerein: Results of a multicenter, randomized, double-blind, controlled trial in patients with knee osteoarthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.3284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
32
|
Chabrun E, Marty M, Zerbib F. Development of esophageal adenocarcinoma on buried glands following radiofrequency ablation for Barrett's esophagus. Endoscopy 2013; 44 Suppl 2 UCTN:E392. [PMID: 23139037 DOI: 10.1055/s-0032-1310245] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- E Chabrun
- Gastroenterology Department, Saint André Hospital, and Université Victor Segalen Bordeaux 2, Bordeaux, France
| | | | | |
Collapse
|
33
|
Djouadi D, Herman P, Besnainou G, Pierrisnard L, Lacaze O, Marty M, Bour F, Cheliout-Heraut F. Traitement des apnées du sommeil chez l’adulte par orthèse mandibulaire. Étude prospective. Neurophysiol Clin 2013. [DOI: 10.1016/j.neucli.2013.01.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
34
|
Harel-Bellan A, Marty M. [100 volumes of Bulletin du Cancer: more than a century in association with the French Cancer Society]. Bull Cancer 2013; 100:107. [PMID: 23589902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
|
35
|
Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost 2013; 11:71-80. [PMID: 23217208 DOI: 10.1111/jth.12071] [Citation(s) in RCA: 201] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although long-term indwelling central venous catheters (CVCs) may lead to pulmonary embolism (PE) and loss of the CVC, there is lack of consensus on management of CVC-related thrombosis (CRT) in cancer patients and heterogeneity in clinical practices worldwide. OBJECTIVES To establish common international Good Clinical Practices Guidelines (GCPG) for the management of CRT in cancer patients. METHODS An international working group of experts was set up to develop GCPG according to an evidence-based medicine approach, using the GRADE system. RESULTS For the treatment of established CRT in cancer patients, we found no prospective randomized studies, two non-randomized prospective studies and one retrospective study examining the efficacy and safety of low-molecular-weight heparin (LMWH) plus vitamin K antagonists (VKAs). One retrospective study evaluated the benefit of CVC removal and two small retrospective studies were on thrombolytic drugs. For the treatment of symptomatic CRT, anticoagulant treatment (AC) is recommended for a minimum of 3 months; in this setting, LMWHs are suggested. VKAs can also be used, in the absence of direct comparisons of these two types of anticoagulants in this setting [Guidance]. The CVC can be kept in place if it is functional, well-positioned and non-infected and there is good resolution under close surveillance; whether the CVC is kept or removed, no standard approach in terms of AC duration has been established [Guidance]. For the prophylaxis of CRT in cancer patients, we found six randomized studies investigating the efficacy and safety of VKA vs. placebo or no treatment, one on the efficacy and safety of unfractionnated heparin, six on the value of LMWH, one double-blind randomized and one non randomized study on thrombolytic drugs and six meta-analyses of AC and CVC thromboprophylaxis. Type of catheter (open-ended like the Hickman(®) catheter vs. closed-ended catheter with a valve like the Groshong(®) catheter), its position (above, below or at the junction of the superior vena cava and the right atrium) and method of placement may influence the onset of CRT on the basis of six retrospective trials, four prospective non-randomized trials, three randomized trials and one meta-analysis. In light of these data: use of AC for routine prophylaxis of CRT is not recommended [1A]; a CVC should be inserted on the right side, in the jugular vein, and distal extremity of the CVC should be located at the junction of the superior vena cava and the right atrium [1A]. CONCLUSION Dissemination and implementation of these international GCPG for the prevention and treatment of CRT in cancer patients at each national level is a major public health priority, needing worldwide collaboration.
Collapse
|
36
|
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56-70. [PMID: 23217107 DOI: 10.1111/jth.12070] [Citation(s) in RCA: 383] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. OBJECTIVES To establish a common international consensus addressing practical, clinically relevant questions in this setting. METHODS An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system. RESULTS For the initial treatment of established VTE: low-molecular-weight heparin (LMWH) is recommended [1B]; fondaparinux and unfractionated heparin (UFH) can be also used [2D]; thrombolysis may only be considered on a case-by-case basis [Best clinical practice (Guidance)]; vena cava filters (VCF) may be considered if contraindication to anticoagulation or pulmonary embolism recurrence under optimal anticoagulation; periodic reassessment of contraindications to anticoagulation is recommended and anticoagulation should be resumed when safe; VCF are not recommended for primary VTE prophylaxis in cancer patients [Guidance]. For the early maintenance (10 days to 3 months) and long-term (beyond 3 months) treatment of established VTE, LMWH for a minimum of 3 months is preferred over vitamin K antagonists (VKA) [1A]; idraparinux is not recommended [2C]; after 3-6 months, LMWH or VKA continuation should be based on individual evaluation of the benefit-risk ratio, tolerability, patient preference and cancer activity [Guidance]. For the treatment of VTE recurrence in cancer patients under anticoagulation, three options can be considered: (i) switch from VKA to LMWH when treated with VKA; (ii) increase in LMWH dose when treated with LMWH, and (iii) VCF insertion [Guidance]. For the prophylaxis of postoperative VTE in surgical cancer patients, use of LMWH o.d. or low dose of UFH t.i.d. is recommended; pharmacological prophylaxis should be started 12-2 h preoperatively and continued for at least 7-10 days; there are no data allowing conclusion that one type of LMWH is superior to another [1A]; there is no evidence to support fondaparinux as an alternative to LMWH [2C]; use of the highest prophylactic dose of LMWH is recommended [1A]; extended prophylaxis (4 weeks) after major laparotomy may be indicated in cancer patients with a high risk of VTE and low risk of bleeding [2B]; the use of LMWH for VTE prevention in cancer patients undergoing laparoscopic surgery may be recommended as for laparotomy [Guidance]; mechanical methods are not recommended as monotherapy except when pharmacological methods are contraindicated [2C]. For the prophylaxis of VTE in hospitalized medical patients with cancer and reduced mobility, we recommend prophylaxis with LMWH, UFH or fondaparinux [1B]; for children and adults with acute lymphocytic leukemia treated with l-asparaginase, depending on local policy and patient characteristics, prophylaxis may be considered in some patients [Guidance]; in patients receiving chemotherapy, prophylaxis is not recommended routinely [1B]; primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic pancreatic [1B] or lung [2B] cancer treated with chemotherapy and having a low risk of bleeding; in patients treated with thalidomide or lenalidomide combined with steroids and/or chemotherapy, VTE prophylaxis is recommended; in this setting, VKA at low or therapeutic doses, LMWH at prophylactic doses and low-dose aspirin have shown similar effects; however, the efficacy of these regimens remains unclear [2C]. Special situations include brain tumors, severe renal failure (CrCl<30 mL min(-1) ), thrombocytopenia and pregnancy. Guidances are provided in these contexts. CONCLUSIONS Dissemination and implementation of good clinical practice for the management of VTE, the second cause of death in cancer patients, is a major public health priority.
Collapse
Affiliation(s)
- D Farge
- Assistance Publique-Hôpitaux de Paris, Internal Medicine and Vascular Disease Unit, Saint-Louis Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Bidard FC, Delaloge S, Giacchetti S, Brain E, de Cremoux P, Vincent-Salomon A, Marty M, Pierga JY. Abstract P2-01-04: Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-01-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Circulating tumor cells (CTCs) isolated by CellSearch® from peripheral blood of metastatic breast patients have been shown as strong independent prognostic factor for progression-free and overall survival. With this technique, the REMAGUS02 prospective multicentric study was the first to report that CTC detection (≥1CTC/7.5ml) before and/or after neoadjuvant chemotherapy was independently associated with distant metastasis-free survival (DMFS, 18 months follow-up, Pierga CCR 2008) and with overall survival (OS, 36 months follow-up, Bidard Ann Oncol 2010).
Patients and Methods: In 115 non-metastatic patients diagnosed with large operable or locally advanced breast cancer, we prospectively detected CTC using the CellSearch system before and after neoadjuvant chemotherapy in the REMAGUS02 trial (Pierga, BCRT 2010). For this report, survival analyses were performed at a median follow-up of 70 months.
Results: After a median follow-up of 70 months, 20 distant metastatic relapses and 14 deaths have been observed among the 115 patients included. CTC detection before chemotherapy (in 23% of patients) is an independent prognostic factor for both DMFS [p = 0.03, relative risk (RR)=3.2] and OS [p = 0.05, RR = 3.7] in multivariate analyses, together with triple negative tumor status. At long-term, CTC detection after chemotherapy (17%) had no clear prognostic significance (p = 0.15 and 0.22, respectively). Complete pathological response as well as tumour size and all other variables tested did not appear as predictive in this model.
Conclusions: Baseline CTC detection is a new independent prognostic factor in the neoadjuvant setting, and is, in this trial, superior to pathological tumor response to predict the survival of non-metastatic breast cancer patients. We confirm therefore our previous results reported with shorter follow-up.
Supported by PHRC AOM/2OO2/02117, Pfizer inc., Roche, sanofi-aventis. ISRCTN10059974
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-01-04.
Collapse
Affiliation(s)
- F-C Bidard
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - S Delaloge
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - S Giacchetti
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - E Brain
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - P de Cremoux
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - A Vincent-Salomon
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - M Marty
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| | - J-Y Pierga
- Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France
| |
Collapse
|
38
|
Giacchetti S, Pierga JY, Asselain B, Delaloge S, Brain E, Espié M, Mathieu MC, Bertheau P, de Cremoux P, Tembo O, Marty M. Abstract P1-14-03: Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without neoadjuvant Trastuzumab for HER2 positive tumor (Remagus 02 trial). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Trastuzumab is indicated in neoadjuvant setting in locally advanced HER2 positive breast cancer patients (Gianni L. Lancet 2010). There is no data on the impact of the use of neoadjuvant Trastuzumab (T) compared to adjuvant T on survival.
Patients and methods: From May 2004 to October 2007, 341 stage II-III breast cancer patients were included in a phase II randomized trial and received 4 cycles (c) of epirubicin (75 mg/m2 d1)–cyclophosphamide (750 mg/m2 d1) q 3 w followed by 4 (c) of docetaxel (100 mg/m2 d1) q 3 w. Pts with HER2+++ tumor (120 pts) were randomized to receive or not neoadjuvant T combined with docetaxel. From September 2005, all pts with HER2+cancer received adjuvant T for a total of 18 c (106 pts). All pts with hormone receptors positive tumor received hormonal treatment according to menopausal status (Pierga et al BCRT 2010). We report here overall survival (OS) and disease free survival (DFS) data at 5 year and associated prognostic factors.
Results: At a median follow up of 49 months, the median DFS was not reached for the whole population and was statistically superior for the HER2 positive cancer patients treated with chemotherapy plus neoadjuvant T compared to the other groups, p = 0.018. The median OS is not reached for the whole population and is statistically higher in HER2 positive tumor group compared to HER2 negative group (p = 0.00077). For 106 HER2 positive breast cancer patients who had received one year of complete trastuzumab treatment, there was no significant difference in OS and DFS between pts who started T in neoadjuvant setting versus in adjuvant setting. DFS and OS were not significantly influenced by pathological Complete Response rate (pCR) (respectively, p = 0.22 and p = 0.56). At multivariate analysis including 6 factors (age, tumor size, clinical lymph node, ER, PgR), factors which influenced OS were tumor size (p = 0.03) and ER expression (p = 0.06) and for DFS, clinical lymph node status (p = 0.049) and PgR expression (p = 0.046).
Conclusion: pCR is not a surrogate of survival in the HER2+subgroup. HER2 positive breast cancer pts receiving trastuzumab have a significant higher OS than those with HER2 negative tumors. OS and DFS do not seem to differ between the neoadjuvant T group and the T adjuvant group.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-03.
Collapse
Affiliation(s)
- S Giacchetti
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - J-Y Pierga
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - B Asselain
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - S Delaloge
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - E Brain
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - M Espié
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - M-C Mathieu
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - p Bertheau
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - P de Cremoux
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - O Tembo
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - M Marty
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| |
Collapse
|
39
|
Mathieu MC, Goubar A, Sigal B, Bertheau P, Guinebretière JM, André F, Pierga JY, Delaloge S, Giacchetti S, Brain E, Marty M. Abstract P3-06-04: Role of pMAPkinase, pAKT, p27 & IGF-IR as predictive markers of response to trastuzumab in patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy + trastuzumab in the REMAGUS02 trial. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-06-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Predicting a benefit from trastuzumab in patients with HER2+ breast cancer remains an important goal. Possible mechanisms of resistance include altered receptor antibody interaction, Akt and MAPK pathways, and loss of p27. The objective of this study was to determine the correlation between pMAPkinase (pMAPK), pAKT, p27, IGF-IR protein expression and the benefit of trastuzumab for patients randomized to chemotherapy (CT) alone and CT with trastuzumab.
Patients and methods: From May 2004 to October 2007, 120 patients with stage II and III HER2+ breast carcinomas were enrolled in a phase II trial of neoadjuvant chemotherapy (CT) with epirubicin-cyclophosphamide (4 courses) followed by docetaxel ± trastuzumab (T) (4 courses). A complete pathological response (pCR) was defined by the absence of residual invasive carcinoma in the breast and axillary lymph nodes. A tissue microarray was constructed from paraffin-embedded tumor samples collected prior to neoadjuvant chemotherapy. Patients' tumours were scored HER2 3+ immunohistochemically (IHC) or 2+ IHC with HER2 amplification by FISH. Immunohistochemical analysis of pMAPK, pAKT, p27 and IGF-IR was performed on tumor tissue microarrays before CT. The H-score (intensity × %) was evaluated. Specimens were classified as exhibiting high or low expression based on a median value as the cut-off point for each marker. A logistic regression model, including the marker and its interaction with treatment, was used to analyse the markers predictive of a treatment effect on the pCR. The independent predictive value was analysed in a multivariate logistic regression adjusting on the lymph node and ER status.
Results: 117/120 (97.5%) patients had sufficient tumor for the analysis. The pCR rate was 19% in the CT arm and 25% in the CT+T arm. The median H-score was: pMAPK = 28, pAKT= 25, p27= 50 and IGF-IR = 15. No significant difference was observed in the pCR rate between the two arms according to pAKT, p27, IGF-IR expression. The pCR rate was higher in CT+T compared to CT alone in patients with high pMAPK expression (OR = 4.7 (0.9–24.2); interaction p = 0.03). No difference was observed in the pCR rate in patients with low pMAPK expression (OR = 0.5 (0.1–1.8).
Conclusions: In HER2-positive breast cancers, pMAPK expression evaluated by IHC was significantly associated with a pathological response in the arm with neoadjuvant trastuzumab. High pMAPK expression could be a predictive marker of response to trastuzumab in a CT +T regimen.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-06-04.
Collapse
Affiliation(s)
- MC Mathieu
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - A Goubar
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - B Sigal
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - P Bertheau
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - JM Guinebretière
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - F André
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - JY Pierga
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - S Delaloge
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - S Giacchetti
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - E Brain
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| | - M Marty
- Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France
| |
Collapse
|
40
|
Giacchetti S, Pierga JY, Delaloge S, Asselain B, Brain E, Guinebretière JM, Che-Lehman J, Mathieu MC, Sigal B, Marty M. Abstract P1-14-18: Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without celecoxib for HER2 negative tumor (Remagus 02 trial). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p1-14-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Cox 2 is frequently over expressed in breast cancers. Celecoxib is a COX-2 inhibitor with anti angiogenic and pro-apoptotic activities. There are few data of anti-COX2 treatment in breast cancers. and no data on the impact of neoadjuvant anti COX 2 agent on survival.
Patients and methods/: From May 2004 to October 2007, 340 stage II-III breast cancer patients were included in a phase II randomized trial and received 4 cycles (c) of epirubicin (75 mg/m2)–cyclophosphamide (750 mg/m2) q 3 w followed by 4 (c) of docetaxel (100 mg/m2) q 3 w. Pts with HER2 negative tumors (220 pts) were randomized to receive or not neoadjuvant celecoxib (200 mg bid) combined with docetaxel. All pts with hormone receptors positive tumor received hormonal treatment according to menopausal status (Pierga et al BCRT 2010). We report here overall survival (OS) and disease free survival (DFS) data and prognostic factors analyses at 5 years.
Results/: At a median follow up of 49 months, the median DFS and OS are not reached for the whole population and none of them is significantly different between pts who received celecoxib or who did not (p = respectively 0.62 and 0.36). Celecoxib had no impact either on clinical and pathological complete response rate (pCR). DFS is significantly higher in patients who achieved pCR as compared to those who did not (p = 0.017; RR = 0.21 [0.051–0.88], whereas OS is borderline significant [p = 0.07; RR = 0.19 (0.026–1.4)]. Patients with triple negative (TN) tumors (78 pts) achieved worst DFS (p = 0.02) and OS (p <0.001) than non triple negative ones despite their higher pCR rate, 29.5 % [95 % CI 19;7-40;9 %] vs 11.4 % in all the other subgroups. At multivariate analysis including 7 factors [tumor size, clinical lymph node, grade (1 vs. 2and 3), pCR, ER, PR, TN], factors which influenced OS and DFS were pCR (p = 0.034 & 0.013 and PgR expression (p = 0.046 & 0.01).
Conclusion/: Celecoxib had no influence on pCR, DFS or OS. Despite higher pCR rate triple negative breast cancer patients' subgroup remains with the poorest outcome.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-18.
Collapse
Affiliation(s)
- S Giacchetti
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - J-Y Pierga
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - S Delaloge
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - B Asselain
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - E Brain
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - JM Guinebretière
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - J Che-Lehman
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - M-C Mathieu
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - B Sigal
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| | - M Marty
- Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France
| |
Collapse
|
41
|
Demoulin C, Marty M, Genevay S, Vanderthommen M, Mahieu G, Henrotin Y. Effectiveness of preventive back educational interventions for low back pain: a critical review of randomized controlled clinical trials. Eur Spine J 2012; 21:2520-30. [PMID: 22836365 PMCID: PMC3508209 DOI: 10.1007/s00586-012-2445-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2012] [Revised: 05/14/2012] [Accepted: 07/11/2012] [Indexed: 12/19/2022]
Abstract
PURPOSE A systematic search was conducted to study the efficiency of preventive educational interventions mainly focused on a biomechanical/biomedical model. METHODS The PubMed electronic database and the Cochrane Library were searched based on a combination of keywords related to low back pain (LBP) and posture education. Only randomized controlled trial (RCT) studying the efficiency on outcomes directly related to LBP of a preventive intervention programme mainly based on education of proper care of the back for subjects not seeking treatment were included. References of the articles meeting these inclusion criteria were also checked to identify other potential citations. Besides, a methodological study assessment of the included RCTs was performed. RESULTS Nine studies, all conducted at the workplace were included in this review. Their mean quality level was low (5.1/12) and among the four studies with a huge sample size (n > 400 subjects), only one had an acceptable methodological quality score (6/12). The education interventions differed widely from one study to another. No significant differences between the control and education groups were found at the follow-up in eight out of the nine studies on the incidence of back pain, disability and sick leave. CONCLUSIONS The results of the RCTs included in this review suggest that educational interventions mainly focused on a biomechanical/biomedical model are not effective in preventing LBP. However, taking into account the methodological quality level of the RCTs as well as the very short and heterogeneous interventions often proposed, additional high-quality studies with a longer education period are needed to conclude that such interventions are inefficient.
Collapse
Affiliation(s)
- C Demoulin
- Department of Motricity Sciences and Rehabilitation, University of Liège, ISEPK (B21), Allée des Sports 4, 4000 Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
42
|
Brun JL, Nocart N, Charbonneau V, Delorme O, Marty M, Garrigue I. O117 HPV DNA AND mRNA EXPRESSION IN CIN2 MIMICS CIN1 MORE THAN CIN3. Int J Gynaecol Obstet 2012. [DOI: 10.1016/s0020-7292(12)60547-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Bouzid K, Bedairia N, Marty M. Anticorps monoclonaux thérapeutiques en cancérologie. ACTA ACUST UNITED AC 2012; 60:223-8. [DOI: 10.1016/j.patbio.2012.05.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Accepted: 04/25/2012] [Indexed: 10/28/2022]
|
44
|
Bedairia N, Morinet F, Marty M. [Cancerology: targets and targeted treatments]. Pathol Biol (Paris) 2012; 60:215-216. [PMID: 22738994 DOI: 10.1016/j.patbio.2012.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/30/2012] [Accepted: 05/03/2012] [Indexed: 06/01/2023]
|
45
|
Farge-Bancel D, Debourdeau P, Beckers M, Baglin C, Bauersachs R, Brenner B, Brilhante D, Falanga A, Gerotziafas G, Kakkar A, Khorana A, Lecumberri R, Mandalà M, Marty M, Monréal M, Mousa S, Nissim H, Noble S, Pabinger I, Prins M, Qari M, Streiff M, Bounameaux H, Büller H. Abstract related to PL-22 Guidelines for antithrombotics in cancer patients. Thromb Res 2012. [DOI: 10.1016/s0049-3848(12)70141-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Duchêne A, Expert A, Debeugny G, Marty M, Demerens T, Ulmann P. Ameli direct – informer sur l’offre de soins hospitalière. Rev Epidemiol Sante Publique 2012. [DOI: 10.1016/j.respe.2011.12.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
47
|
Feugeas JP, Dumay A, Lehmann-Che J, de CP, Delord M, Soulier J, Hamy AS, Espié M, André F, Marty M, Sotiriou C, Piccart-Gebhart M, Pusztai L, Bertheau P, de TH. P3-05-01: Gene Profiling of Histopathologically Characterized Apocrine Breast Cancers. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer is currently classified in 3 groups based on estrogen receptor alpha (ER) and human epidermal growth factor receptor 2 (HER2/ERBB2) gene expression: one basal-like (ER-ERBB2-), one HER2−enriched (ERBB2+) and one luminal (ER+). Yet, in transcriptome-based classifications, ER-ERBB2+ group partially overlaps with more recently defined ER-AR+ (androgen receptor positive) group. This type was named molecular apocrine, in reference to the histopathologically characterized apocrine carcinomas (H-Apo), in which a marked activation of AR signaling was demonstrated with a distinct proteomic signature. H-Apo tumors correspond to 1% of invasive breast carcinomas and are clearly morphological distinct from other AR+ tumors. However, no specific H-Apo transcriptome signature has been reported for this sub-group. In an effort to better characterize those tumors, we have performed a meta-analysis of genomic data, focusing on the ER- AR+ breast subset.
Samples and Methods: Chips were from Affymetrix array generations HG-U133. 258 profiles were unpublished and 1145 were from published or in press data. Gene expression was carried out after GC-RMA normalization. Unsupervised hierarchical clustering and other statistical analysis were performed with R software.
Results: 160 of the 1403 investigated tumors were ER-AR+. An unsupervised hierarchical clustering clearly identified a small subgroup of 14 closely tumors expressing high transcripts levels of PIP, HPGD, ACSM1, AR, SDR5A1, HS3DB1. This profile was very similar to the proteomic signature previously described for the H-Apo tumors. In addition, the pathology report, although available only for 4 of those14 tumors, described them as typical apocrine carcinomas. Taken together, these data suggested that this cluster was the H-Apo subgroup. Unexpectedly, when using the transcriptomic PAM50 classification, 13 were classified as Luminal and only 1 as HER2−enriched, although the 14 tumors were all ER-negative. CGH analysis with Agilent 244K chips was carried out with 25 ER- AR+ tumors, of which 5 were H-Apo carcinomas. Importantly, those 5 H-Apo tumors exhibited fewer DNA lesions than the other ER-AR+ apocrine tumors (17% copy number alterations in H-Apo group versus 41%, p=0.02). More CGH data are currently under investigations and will be discussed.
Discussion: The histopathologically characterized apocrine carcinomas (H-Apo) display transcriptomic signs of active androgen metabolism and fewer DNA lesions than others molecular apocrine tumors. This could suggest that molecular apocrine and H-apocrine tumor derive from the same cell of origin, but that only H-Apo retains morphological apocrine features, possibly due to the presence of fewer genetic lesions. In any case, the prominent androgen signaling activation warrants functional assays of anti-androgen in these breast cancer subtypes.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-05-01.
Collapse
Affiliation(s)
- J-P Feugeas
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - A Dumay
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - J Lehmann-Che
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - Cremoux P de
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Delord
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - J Soulier
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - A-S Hamy
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Espié
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - F André
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Marty
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - C Sotiriou
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Piccart-Gebhart
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - L Pusztai
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - P Bertheau
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - Thé H de
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| |
Collapse
|
48
|
Reyal F, Valet F, de Cremoux P, Mathiot C, Decraene C, Asselain B, Brain E, Delaloge S, Giacchetti S, Marty M, Pierga JY, Bidard FC. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann Oncol 2011; 22:1458-1459. [PMID: 21525400 DOI: 10.1093/annonc/mdr144] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | - C Decraene
- Department of Translational Research, Institut Curie, Paris
| | | | - E Brain
- Department of Medical Oncology, Hospital René Huguenin, Institut Curie, Saint Cloud
| | - S Delaloge
- Department of Medicine, Institut Gustave Roussy, Villejuif
| | - S Giacchetti
- Department of Medical Oncology, Hópital Saint Louis, Paris
| | - M Marty
- Department of Medical Oncology, Hópital Saint Louis, Paris
| | - J Y Pierga
- Department of Medical Oncology, Institut Curie, Paris; University Paris Descartes, Paris, France
| | - F C Bidard
- Department of Medical Oncology, Institut Curie, Paris; University Paris Descartes, Paris, France.
| |
Collapse
|
49
|
Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Deschamp V. P343 CARIATIDE trial: the impact of educational materials (EM) on patients' compliance with adjuvant aromatase inhibitor (AI) therapy and quality of life (QoL). Breast 2011. [DOI: 10.1016/s0960-9776(11)70279-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Scafidi P, Ignat M, Mortini P, Marty M. An Analysis by Scanning Acoustic Microscopy of the Mechanical Stability of PSG and Si3N4 Passivation Films. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-338-115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTTwo types of mechanical tests associated with acoustic microscopy characterizations were performed to investigate the mechanical stability of PSG and Si3N4 passivation films. An in situ tensile test micro-device was installed under a scanning acoustic microscope to study the damage development in the passivation films deposited on A1,1%Si substrates. The analysis of the attenuation of the acoustic signature of the film/substrate systems and the variations of the leaky surface acoustic wave velocity permitted detection of the cracking and decohesion of the passivation films. The four-point bending test was used to submit passivated aluminum multilayers deposited on silicon substrates to cyclic compression. Then subsurface acoustic images revealed decohered zones in the passivation.
Collapse
|